Alphatec Holdings, Inc. develops medical technology for spine surgery, with a business centered on procedural spine solutions, surgical instrumentation, imaging, navigation and informatics. Company updates commonly address surgical revenue trends, EOS revenue, surgeon adoption, product launches such as Valence and EOS Insight, and the continued development of its InformatiX platform through subsidiaries including Alphatec Spine, EOS imaging and SafeOp Surgical.
Recurring developments also include financing actions, credit-facility activity, strategic partnerships tied to spinal fusion and regenerative technology, profitability metrics and annual outlook updates. Governance items, including board composition changes, appear alongside operating results and capital-structure announcements.
Alphatec Holdings, Inc. (NASDAQ: ATEC) announced it will release its first quarter financial results on May 4, 2023, after the market closes. A live webcast will be hosted at 1:30 p.m. PT / 4:30 p.m. ET. Investors can access the webcast by visiting ATEC's Investor Relations Section. Following the webcast, a replay will be available for twelve months on the website, with a dial-in replay option starting two hours after the event. ATEC focuses on revolutionizing spine surgery with innovative solutions, emphasizing their Organic Innovation Machine™ and expanding AlphaInformatiX Platform.
Alphatec Holdings, Inc. (Nasdaq: ATEC) has announced participation in key investor events. The company will present at The Needham Virtual Healthcare Conference on April 17, 2023, at 12:45pm ET, and at The Bank of America Healthcare Conference in Las Vegas, NV, on May 9, 2023, at 9:20am PT. Webcasts of these presentations will be available in the Investor Relations Section of the company’s website. Additionally, ATEC has granted 33,520 restricted stock units (RSUs) to sixteen new employees as part of its employment inducement program, which will vest over four years or upon a change of control.
Alphatec Holdings, Inc. (ATEC) reported a full-year revenue increase of 44%, reaching $351 million, and $106 million for Q4 2022, a 43% year-over-year growth. The company's adjusted EBITDA margin for Q4 improved by 750 basis points. Full-year 2022 operating expenses stood at $380 million, resulting in a GAAP operating loss of $147 million. Looking ahead, ATEC projects a revenue of approximately $438 million for 2023, indicating a 25% growth, with expectations to achieve non-GAAP adjusted EBITDA break-even.
Alphatec Holdings, Inc. (NASDAQ: ATEC) announced management participation in several upcoming investor events. These include the Cowen Healthcare Conference on March 6, 2023, in Boston at 2:10 pm ET, and the Canaccord Genuity Musculoskeletal Conference in Las Vegas on March 7, 2023, at 2:30 pm PT. Other events include a virtual presentation at the Loop Capital Markets Annual Investor Conference on March 13, 2023, and the Barclays Healthcare Conference in Miami on March 15, 2023, at 2:05 pm ET. Webcasts and archived recordings of these events will be accessible via the Company’s Investor Relations section on their website.
Alphatec Holdings, Inc. (ATEC) will release its fourth quarter and fiscal year 2022 financial results on February 28, 2023, after market close. A live webcast will follow at 1:30 p.m. PT / 4:30 p.m. ET. Additionally, ATEC has granted 12,108 restricted stock units (RSUs) to seven new employees as an inducement for their employment, vesting in annual installments over four years, with full vesting upon a change of control. ATEC aims to innovate spine surgery with its Organic Innovation Machine™ and the AlphaInformatiX Platform.
Alphatec Holdings, Inc. (ATEC) reported notable preliminary financial results for Q4 and FY 2022, with total revenue rising approximately 44% to over $350 million. The company predicts a 25% revenue growth in 2023, anticipating $438 million, alongside achieving break-even adjusted EBITDA. ATEC secured a $150 million non-dilutive term loan to bolster its balance sheet, enhancing liquidity to around $275 million. Surgical revenue increased by 48% to 50%, reflecting strong adoption of the PTP™ approach. The firm plans to continue expanding its market presence in spine surgery.
Alphatec Holdings, Inc. (NASDAQ: ATEC) announced its participation in the 25th Annual Needham Growth Conference with a fireside chat scheduled for January 12, 2023, at 3:00 PM ET. The presentation will be available via webcast in the Company’s Investor Relations Section.
Additionally, the Company granted 18,048 restricted stock units to 16 new employees as part of its employment inducement awards.
Alphatec Holdings, Inc. (ATEC) reported a strong 43% growth in total revenue, reaching $90 million for Q3 2022, driven by a 53% increase in surgical revenue. The company achieved a 66% GAAP gross margin and a 71% non-GAAP gross margin. Despite operating expenses of $94 million, adjusted EBITDA improved significantly, with a margin increase of 870 basis points year-over-year. ATEC anticipates total revenue of $340 million for the full year, in line with a 40% growth rate forecasted earlier.
Alphatec Holdings, Inc. (NASDAQ: ATEC) announced participation in several investor events aimed at discussing spine surgery innovations. Key events include a fireside chat at the Stifel 2022 Healthcare Conference on November 15, 2022, and the Jefferies London Healthcare Conference on November 17, 2022. Additionally, ATEC will present at the Piper Sandler Healthcare Conference on November 30, 2022, and host a visit from the Stifel Medtech Madness Annual West Coast Bus Tour on December 12, 2022. Webcasts and archived recordings will be accessible on the Investor Relations section of ATEC's website.
Alphatec Holdings, Inc. (ATEC) announced its participation in the 2022 NASS Annual Meeting, where it will unveil its new expandable interbody and access technology aimed at enhancing minimally-invasive spine surgery. This innovative approach minimizes muscle damage and blood loss, leading to shorter hospital stays and quicker recovery for patients. The Sigma Medialized Access System and PSX Expandable Interbody Implant System are designed to improve surgical outcomes by allowing precise control of spinal alignment and disc height restoration.